Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences
Harpoon Therapeutics, a clinical-stage immunotherapy company, announced that its CEO Gerald McMahon will participate in two upcoming virtual investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Harpoon Therapeutics, a clinical-stage immunotherapy company, announced that its CEO Gerald McMahon will participate in two upcoming virtual investor conferences. The first is a panel discussion titled “Heavenly (anti)Bodies” at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021, at 1:10 p.m. ET. The second is a presentation at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 10:30 a.m. ET, with a live webcast available on the company’s website.
Harpoon is developing innovative T cell engagers to treat cancer and other diseases.
Details
News Market Reaction – HARP
The recorded move for HARP in the trading session of this news was -0.20%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences:
- A panel discussion titled “Heavenly (anti)Bodies” at the 2021 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 10, 2021 at 1:10 p.m. ET / 10:10 a.m. PT; and
- A presentation at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021 at 10:30 a.m. ET / 7:30 a.m. PT. A live webcast of the Canaccord presentation will be available from the Events and Presentations section of the company’s website at https://ir.harpoontx.com/events-and-presentations and will be archived there shortly after the event.
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.
Contacts:
Harpoon Therapeutics, Inc.
Georgia Erbez
Chief Financial Officer
650-443-7400
media@harpoontx.com
Westwicke ICR
Robert H. Uhl
Managing Director
858-356-5932
robert.uhl@westwicke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.